Neurocrine Biosciences (NASDAQ: NBIX) Shows Strong Financials and Strategic Growth

• Neurocrine Biosciences (NASDAQ: NBIX) reported strong Q2 2026 financials, with total revenues of $959 million (a 39% increase) and non-GAAP earnings of $2.85 per share, significantly exceeding estimates.
• Citigroup (NYSE: C) maintained a "Buy" rating and raised its price target for Neurocrine Biosciences to $249, reflecting a positive analyst outlook.
• The company is pursuing strategic growth through the acquisition of Soleno Therapeutics (NASDAQ: SLNO) and advancing its clinical pipeline with key Phase III results anticipated in 2027.

Neurocrine Biosciences is a biopharmaceutical company with a market capitalization of approximately $16.75 billion. The company focuses on developing treatments for neurological and endocrine-related diseases and disorders. Its activities include the commercialization of products like INGREZZA and advancing a pipeline of potential new medicines through clinical trials.

On July 31, 2026, the analyst firm Citigroup maintained its "Buy" rating for Neurocrine Biosciences. A "Buy" rating suggests that analysts believe the stock's price will increase in the future. Citigroup also raised its price target, which is a projection of the stock's future value, to $249 from $246, as highlighted by TheFly.

This positive outlook is supported by the company's strong financial results. For the second quarter of 2026, Neurocrine Biosciences reported total revenues of $959 million, a 39% increase from the same period last year. It also announced non-GAAP earnings of $2.85 per share, which significantly surpassed the Zacks Consensus Estimate of $2.26.

The company's revenue growth is driven by its expanding commercial portfolio. Sales for its key product, INGREZZA, increased by 15% year-over-year. Based on this performance, Neurocrine Biosciences raised its 2026 net sales guidance for INGREZZA to a range of $2.825 billion to $2.875 billion, signaling confidence in continued sales momentum.

Neurocrine Biosciences is also executing a strategy for future growth by expanding its business. The company recently completed the acquisition of Soleno Therapeutics in May 2026. It is also advancing its clinical pipeline, with important Phase III results for its osavampator and direclidine programs expected in 2027.